Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine

Journal of Toxicological Sciences

Volumn 38, Issue 5, 2013, Pages 741-752

  Fang, Jia Long ^a   Beland, Frederick A ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Apoptosis; Cell cycle; Cell senescence; Nevirapine; Reverse transcriptase

Indexed keywords

BETA GALACTOSIDASE; LACTATE DEHYDROGENASE; NEVIRAPINE; PHOSPHOPROTEIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; LIVER CELL; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

APOPTOSIS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HEPATOCYTES; HUMANS; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886036984     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.38.741     Document Type: Article

References (33)

1. Allen, M., Millett, P., Dawes, E. and Rushton, N. (1994): Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. Clin. Mater., 16, 189-194.
2. Boxwell, D., Haverkos, H., Kukich, S., Struble, K. and Jolson, H. (2001): Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--Worldwide, 1997-2000. MMWR, 49, 1153-1156.
3. Calmy, A., Hirschel, B., Cooper, D.A. and Carr, A. (2009): A new era of antiretroviral drug toxicity. Antivir. Ther., 14, 165-179.
4. Clotet, B. (2008): Once-daily dosing of nevirapine in HAART. J. Antimicrob. Chemother., 61, 13-16.
5. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U.M., Wenz, C., Lingner, J., Kraut, N., Rettig, W.J. and Schnapp, A. (2001): A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20, 6958-6968.
6. de Clercq, E. (1998): The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res., 38, 153-179.
7. de Maat, M.M., ter Heine, R., Mulder, J.W., Meenhorst, P.L., Mairuhu, A.T., van Gorp, E.C., Huitema, A.D. and Beijnen, J.H. (2003): Incidence and risk factors for nevirapine-associated rash. Eur. J. Clin. Pharmacol., 59, 457-462.
8. de Maat, M.M., Mathot, R.A., Veldkamp, A.I., Huitema, A.D., Mulder, J.W., Meenhorst, P.L., Van Gorp, E.C., Carlier, H. and Beijnen, J.H. (2002): Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals. Pharmacol. Res., 46, 295-300.
9. Dieterich, D.T., Robinson, P.A., Love, J. and Stern, J.O. (2004): Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis., 38, S80-S89.
10. Fang, J.-L. and Beland, F.A. (2009): Long-term exposure to zidovudine delays cell cycle progression, induces apoptosis, and decreases telomerase activity in human hepatocytes. Toxicol. Sci., 111, 120-130.
11. Fang, J.-L., McGarrity, L.J. and Beland, F.A. (2009): Interference of cell cycle progression by zidovudine and lamivudine in NIH 3T3 cells. Mutagenesis, 24, 133-141.
12. Freund, A., Patil, C.K. and Campisi, J. (2011): p38MAPK is a novel DNA damage response-independent regulator of the senescence- associated secretory phenotype. EMBO J., 30, 1536-1548.
13. Harris, M. and Montaner, J.S.G. (2000): Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev. Med. Virol., 10, 217-229.
14. Landriscina, M., Altamura, S.A., Roca, L., Gigante, M., Piscazzi, A., Cavalcanti, E., Costantino, E., Barone, C., Cignarelli, M., Gesualdo, L. and Ranieri, E. (2008): Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int. J. Cancer, 122, 2842-2850.
15. Landriscina, M., Fabiano, A., Altamura, S., Bagala, C., Piscazzi, A., Cassano, A., Spadafora, C., Giorgino, F., Barone, C. and Cignarelli, M. (2005): Reverse transcriptase inhibitors down- regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. J. Clin. Endocrinol. Metab., 90, 5663-5671.
16. Levine, A.J., Hu, W. and Feng, Z. (2006): The P53 pathway: what questions remain to be explored? Cell Death Differ., 13, 1027-1036.
17. Lockman, S., Shapiro, R.L., Smeaton, L.M., Wester, C., Thior, I., Stevens, L., Chand, F., Makhema, J., Moffat, C., Asmelash, A., Ndase, P., Arimi, P., van Widenfelt, E., Mazhani, L., Novitsky, V., Lagakos, S. and Essex, M. (2007): Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med., 356, 135-147.
18. Mangiacasale, R., Pittoggi, C., Sciamanna, I., Careddu, A., Mattei, E., Lorenzini, R., Travaglini, L., Landriscina, M., Barone, C., Nervi, C., Lavia, P. and Spadafora, C. (2003): Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Oncogene, 22, 2750-2761.
19. Manosuthi, W., Thongyen, S., Chumpathat, N., Muangchana, K. and Sungkanuparph, S. (2006): Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. HIV Med., 7, 378-382.
20. Martinez, E., Blanco, J.L., Arnaiz, J.A., Perez-Cuevas, J.B., Mocroft, A., Cruceta, A., Marcos, M.A., Milinkovic, A., Garcia-Viejo, M.A., Mallolas, J., Carne, X., Phillips, A. and Gatell, J.M. (2001): Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS, 15, 1261-1268.
21. Pav, J.W., Rowland, L.S. and Korpalski, D.J. (1999): HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J. Pharm. Biomed. Anal., 20, 91-98.
22. PDR (2009): Viramune (Nevirapine). Physicians' Desk Reference. In: Physicians' Desk Reference, pp. 873-881, Medical Economics Co., Montvale, NJ.
23. Pittoggi, C., Martis, G., Mastrangeli, G., Mastrangeli, B. and Spadafora, C. (2008): In vitro evidence for a new therapeutic approach in renal cell carcinoma. Int. Braz J. Urol., 34, 492-502.
24. Pyra, H., Boni, J. and Schupbach, J. (1994): Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc. Natl. Acad. Sci. USA, 91, 1544-1548.
25. Rodier, F., Coppe, J.P., Patil, C.K., Hoeijmakers, W.A., Munoz, D.P., Raza, S.R., Freund, A., Campeau, E., Davalos, A.R. and Campisi, J. (2009): Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol., 11, 973-979.
26. Sancar, A., Lindsey-Boltz, L.A., Unsal-Kacmaz, K. and Linn, S. (2003): Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann. Rev. Biochem., 73, 39-85.
27. Sciamanna, I., Landriscina, M., Pittoggi, C., Quirino, M., Mearelli, B., Beraldi, R., Mattei, E., Serafino, A., Cassano, A., Sinibaldi-Vallebona, P., Garaci, E., Barone, C. and Spadafora, C. (2004): Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene, 24, 3923-3931.
28. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D. and Lowe, S.W. (1997): Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88, 593-602.
29. Smith, P.F., DiCenzo, R. and Morse, G.D. (2001): Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin. Pharmacokinet. 40, 893-905.
30. Stefanidis, K., Loutradis, D., Vassiliou, L.V., Anastasiadou, V., Kiapekou, E., Nikas, V., Patris, G., Vlachos, G., Rodolakis, A. and Antsaklis, A. (2008): Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Gynecol. Oncol., 111, 344-349.
31. Sugrue, M.M., Shin, D.Y., Lee, S.W. and Aaronson, S.A. (1997): Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl. Acad. Sci. USA, 94, 9648-9653.
32. Taiwo, B.O. (2006): Nevirapine toxicity. Int. J. STD AIDS, 17, 364-369.
33. Wang, Y., Blandino, G., Oren, M. and Givol, D. (1998): Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene, 17, 1923-1930.